Literature DB >> 17122617

A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection.

Henrik Petrowsky1, Lucas McCormack, Martha Trujillo, Markus Selzner, Wolfram Jochum, Pierre-Alain Clavien.   

Abstract

OBJECTIVE: To evaluate whether ischemic preconditioning (IP) with continuous clamping or intermittent clamping (IC) of the portal triad confers better protection during liver surgery. SUMMARY BACKGROUND DATA: IP and IC are distinct protective approaches against ischemic injury. Since both strategies proved to be superior in randomized controlled trials (RCTs) to continuous inflow occlusion alone, we designed a RCT to compare IP and IC in patients undergoing major liver resection.
METHODS: Noncirrhotic patients undergoing major liver resection were randomized to receive IP with inflow occlusion (n = 36) or IC (n = 37). Primary endpoints were postoperative liver injury and intraoperative blood loss. Postoperative liver injury was assessed by peak values of AST (alanine aminotransferase) and ALT (aspartate aminotransferase), as well as the area under the curve (AUC) of the postoperative transaminase course. Secondary endpoints included resection time, the need of blood transfusion, ICU, and hospital stay as well as postoperative complications and mortality.
RESULTS: Both groups were comparable regarding demographics, ASA score, type of hepatectomy, duration of inflow occlusion (range, 30-75 minutes), and resection surface. The transection-related blood loss was 146 versus 250 mL (P = 0.008), and when standardized to the resection surface 1.2 versus 1.8 mL/cm (P = 0.01) for IP and IC, respectively. Although peak AST, AUCAST, and AUCALT were lower for IC, the differences did not reach statistical significance. Overall (42% vs. 38%) and major (33 vs. 27%) postoperative complications as well as median ICU (1 vs. 1 day) and hospital stay (10 vs. 11 days) were similar between both groups.
CONCLUSIONS: Both IP and IC appear to be equally effective in protecting against postoperative liver injury in noncirrhotic patients undergoing major liver resection. However, IP is associated with lower blood loss and shorter transection time. Therefore, both strategies can be recommended for noncirrhotic patients undergoing liver resection.

Entities:  

Mesh:

Year:  2006        PMID: 17122617      PMCID: PMC1856627          DOI: 10.1097/01.sla.0000246834.07130.5d

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  38 in total

1.  Control of intraoperative bleeding during liver resection: analysis of a questionnaire sent to 231 Japanese hospitals.

Authors:  Yasuaki Nakajima; Tsuyoshi Shimamura; Toshiya Kamiyama; Michiaki Matsushita; Naoki Sato; Satoru Todo
Journal:  Surg Today       Date:  2002       Impact factor: 2.549

2.  Incidence and management of bile leakage after hepatic resection for malignant hepatic tumors.

Authors:  Shogo Tanaka; Kazuhiro Hirohashi; Hiromu Tanaka; Taichi Shuto; Sang Hun Lee; Shoji Kubo; Shigekazu Takemura; Takatsugu Yamamoto; Takahiro Uenishi; Hiroaki Kinoshita
Journal:  J Am Coll Surg       Date:  2002-10       Impact factor: 6.113

3.  Safety of hemihepatic vascular occlusion during resection of the liver.

Authors:  M Makuuchi; T Mori; P Gunvén; S Yamazaki; H Hasegawa
Journal:  Surg Gynecol Obstet       Date:  1987-02

4.  Ischemic preconditioning protects the mouse liver by inhibition of apoptosis through a caspase-dependent pathway.

Authors:  S S Yadav; D Sindram; D K Perry; P A Clavien
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

5.  Ischemic preconditioning modulates the expression of several genes, leading to the overproduction of IL-1Ra, iNOS, and Bcl-2 in a human model of liver ischemia-reperfusion.

Authors:  Alain Barrier; Natalia Olaya; Franck Chiappini; François Roser; Olivier Scatton; Cédric Artus; Brigitte Franc; Sandrine Dudoit; Antoine Flahault; Brigitte Debuire; Daniel Azoulay; Antoinette Lemoine
Journal:  FASEB J       Date:  2005-10       Impact factor: 5.191

6.  Continuous versus intermittent portal triad clamping for liver resection: a controlled study.

Authors:  J Belghiti; R Noun; R Malafosse; P Jagot; A Sauvanet; F Pierangeli; J Marty; O Farges
Journal:  Ann Surg       Date:  1999-03       Impact factor: 12.969

7.  Tolerance of the human liver to prolonged normothermic ischemia. A biological study of 20 patients submitted to extensive hepatectomy.

Authors:  C Huguet; B Nordlinger; P Bloch; J Conard
Journal:  Arch Surg       Date:  1978-12

Review 8.  Protective strategies against ischemic injury of the liver.

Authors:  Nazia Selzner; Hannes Rudiger; Rolf Graf; Pierre-Alain Clavien
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

9.  Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases.

Authors:  David A Kooby; Jennifer Stockman; Leah Ben-Porat; Mithat Gonen; William R Jarnagin; Ronald P Dematteo; Scott Tuorto; David Wuest; Leslie H Blumgart; Yuman Fong
Journal:  Ann Surg       Date:  2003-06       Impact factor: 12.969

10.  Sub-lethal oxidative stress triggers the protective effects of ischemic preconditioning in the mouse liver.

Authors:  Hannes A Rüdiger; Rolf Graf; Pierre-Alain Clavien
Journal:  J Hepatol       Date:  2003-12       Impact factor: 25.083

View more
  59 in total

1.  [Ischemic preconditioning in major resection of the liver. No additional benefit from intermittent Pringle maneuver].

Authors:  O Strobel; M W Büchler
Journal:  Chirurg       Date:  2012-01       Impact factor: 0.955

2.  Non-cirrhotic liver tolerance to intermittent inflow occlusion during laparoscopic liver resection.

Authors:  Alberto Patriti; Cecilia Ceribelli; Graziano Ceccarelli; Alberto Bartoli; Raffaele Bellochi; Luciano Casciola
Journal:  Updates Surg       Date:  2012-03-06

Review 3.  Ischemia and reperfusion--from mechanism to translation.

Authors:  Holger K Eltzschig; Tobias Eckle
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

4.  Serotonin reverts age-related capillarization and failure of regeneration in the liver through a VEGF-dependent pathway.

Authors:  Katarzyna Furrer; Andreas Rickenbacher; Yinghua Tian; Wolfram Jochum; Anne Greet Bittermann; Andres Käch; Bostjan Humar; Rolf Graf; Wolfgang Moritz; Pierre-Alain Clavien
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

5.  Vascular clamping in liver surgery: physiology, indications and techniques.

Authors:  Elie K Chouillard; Andrew A Gumbs; Daniel Cherqui
Journal:  Ann Surg Innov Res       Date:  2010-03-26

6.  Right hepatectomy with extra-hepatic vascular division prior to transection: intention-to-treat analysis of a standardized policy.

Authors:  Emmanuel Boleslawski; Gauthier Decanter; Stéphanie Truant; Ahmed Fouad Bouras; Lasha Sulaberidze; Olivier Oberlin; François-René Pruvot
Journal:  HPB (Oxford)       Date:  2012-07-04       Impact factor: 3.647

Review 7.  Surrogate endpoints in liver surgery related trials: a systematic review of the literature.

Authors:  Liliane Mpabanzi; Kim M C van Mierlo; Massimo Malagó; Cornelis H C Dejong; Dimitrios Lytras; Steven W M Olde Damink
Journal:  HPB (Oxford)       Date:  2012-10-22       Impact factor: 3.647

Review 8.  Attenuating myocardial ischemia by targeting A2B adenosine receptors.

Authors:  Holger K Eltzschig; Stephanie K Bonney; Tobias Eckle
Journal:  Trends Mol Med       Date:  2013-03-26       Impact factor: 11.951

9.  Transcriptional responses in the adaptation to ischaemia-reperfusion injury: a study of the effect of ischaemic preconditioning in total knee arthroplasty patients.

Authors:  Terence Murphy; Pauline M Walsh; Peter P Doran; Kevin J Mulhall
Journal:  J Transl Med       Date:  2010-05-10       Impact factor: 5.531

10.  IVC CLAMP: infrahepatic inferior vena cava clamping during hepatectomy--a randomised controlled trial in an interdisciplinary setting.

Authors:  Nuh N Rahbari; Johannes B Zimmermann; Moritz Koch; Thomas Bruckner; Thomas Schmidt; Heike Elbers; Christoph Reissfelder; Markus A Weigand; Markus W Büchler; Jürgen Weitz
Journal:  Trials       Date:  2009-10-13       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.